Abstract

The human DLX homeobox genes, which are related to Dll (Drosophila distal-less gene), encode transcription factors that are expressed primarily in embryonic development. Recently, DLX5 was reported to act as an oncogene in lymphomas and lung cancers, although the mechanism is not known. The identification of target genes of DLX5 can facilitate our understanding of oncogenic mechanisms driven by overexpression of DLX5. The MYC oncogene is aberrantly expressed in many human cancers and regulates transcription of numerous target genes involved in tumorigenesis. Here we demonstrate by luciferase assay that the MYC promoter is specifically activated by overexpression of DLX5 and that two DLX5 binding sites in the MYC promoter are important for transcriptional activation of MYC. We also show that DLX5 binds to the MYC promoter both in vitro and in vivo and that transfection of a DLX5 expression plasmid promotes the expression of MYC in a dose-dependent manner in mammalian cells. Furthermore, overexpression of DLX5 results in increased cell proliferation by up-regulating MYC. Knockdown of DLX5 in lung cancer cells overexpressing DLX5 resulted in decreased expression of MYC and reduced cell proliferation, which was rescued by overexpression of MYC. Because DLX5 has a restricted pattern of expression in adult tissues, it may serve as a potential therapeutic target for the treatment of cancers that overexpress DLX5.

Highlights

  • Homeobox genes are characterized by a 180-base pair DNA segment encoding a highly conserved 60-amino acid DNAbinding domain

  • Expression of Dlx5 Correlates with Myc Expression in LckMyr-Akt2 Lymphomas—In previous studies of thymic lymphomas from Lck-Myr-Akt2 mice, we reported a novel recurrent inv[6] that leads to robust expression of Dlx5 [36]

  • The Dlx5 and Dlx6 homeobox genes are co-expressed in all skeletal structures found in midgestation embryos after the initial formation of cartilage

Read more

Summary

The abbreviations used are

Lck-Myr-Akt, transgene encoding myristoylated (active) form of Akt kinase, driven by the Lck (lymphocyte-specific protein-tyrosine kinase) gene promoter; NSCLC, non-small cell lung cancer; siRNA, small interfering RNA; RT, reverse transcription; ChIP, chromatin immunoprecipitation. Regulation of MYC by DLX5 leukemia cells leads to a reduction in MYC expression [38]. We report that DLX5 directly binds the MYC promoter and can promote tumor cell proliferation by up-regulating MYC

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call